Product Disclosures

Reflecting standard oncology practice, which often requires the off-label or investigational use of some products, this educational activity does not include information about many drugs. All faculty participating in continuing education activities are expected to disclose the approved or investigational status (related to the subject matter of this virtual lecture—colorectal cancer) of all products and devices under discussion. This information, as of the time of printing, is summarized briefly in the table below. In addition, primary references and full prescribing information should be consulted for complete information. Clinicians have the professional responsibility to ensure that drugs are prescribed and used appropriately, based on their own clinical judgment and accepted standards of care.

Generic Name	Brand Name	FDA Approved for the Treatment of Colorectal Cancer	FDA Approved for Other Indications	Investigational for the Treatment of Colorectal Cancer
Acetaminophen	Tylenol		X
Aminophylline	Various		X
Atropine	Various		X
Bevacizumab	Avastin	X
Capecitabine	Xeloda	X	X
Cetuximab	Erbitux	X	X
Cisplatin	Platinol		X
Diphenhydramine	Benadryl		X
Epinephrine	Various		X
Erlotinib	Tarceva		X
5-Fluorouracil (5-FU)	Adrucil	X	X
Gefitinib	Iressa		X
Irinotecan	Camptosar	X
Leucovorin (folinic acid)	Wellcovorin	X	X
Levamisole*	Ergamisol	X
Oxaliplatin	Eloxatin	X
Panitumumab	N/A			X
Pyridoxine (vitamin B₆)	Various		X
Vatalanib	N/A			X
No longer marketed in the United States. N/A = not applicable. Adapted from Drug Facts and Comparisons*. St Louis, Mo: Facts & Comparisons; 2006. Agents may be approved for use in combination. The only investigational agent for the treatment of peripheral sensory neuropathy discussed in this text is Xaliproden.